Tiragolumab Impresses in Multiple Trials

Cancer Discov. 2020 Aug;10(8):1086-1087. doi: 10.1158/2159-8290.CD-NB2020-063. Epub 2020 Jun 23.


The TIGIT inhibitor tiragolumab, alone or in combination with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers. In phase I and II trials, the agent achieved statistically significant results in multiple solid malignancies-most notably non-small cell lung cancer.

Publication types

  • News